Durability of response to vaccination against viral hepatitis A in HIV-infected patients: a 5-year observation.
The aim of this study was to estimate the prevalence of total antibodies to hepatitis A virus (anti-HAV-T) in the group of HIV-positive adults in Lodz region of Poland, and to evaluate the response and long-term immunity after vaccination against hepatitis A virus. In the group of 234 HIV-infected patients, 72 persons (30.8%) were anti-HAV-T positive (>20 IU/L). In multivariate analysis, two independent factors associated with the presence of anti-HAV-T were identified: the age of patients (OR = 1.07) and the presence of antibodies to hepatitis C virus (OR = 2.87). Vaccination was completed in 83 patients. Good response (anti-HAV-T >20 IU/L one month after the booster dose) was obtained in 79.5% of patients. In patients with CD4 >200 cells/µL in multivariate analysis only presence of antibodies to hepatitis C virus was a prognostic factor for the response to vaccination (OR = 0.13). Among responders available for the follow-up, 82% (50 out of 61) had detectable anti-HAV-T at 1 year and 75.5% (37 out of 49) at 5 years. Our results demonstrate that most of the studied HIV-positive patients were susceptible to hepatitis A virus infection. Most HIV-infected adults with high CD4 counts had a durable response even up to 5 years after vaccination. Patients with a HIV/hepatitis C virus coinfection displayed a worse response to vaccination.
Department of Infectious Diseases and Hepatology, Medical University of Łódź, Łódź, Poland elajablonowska@gmail.com.
E
E
Jabłonowska
Department of Infectious Diseases and Hepatology, Medical University of Łódź, Łódź, Poland.
J
J
Kuydowicz
D000328:Adult; D015992:Body Mass Index; D018791:CD4 Lymphocyte Count; D005260:Female; D015658:HIV Infections / Q000150:complications* / Q000276:immunology* / Q000821:virology; D006506:Hepatitis A / Q000453:epidemiology / Q000517:prevention & control*; D035922:Hepatitis A Antibodies / Q000097:blood*; D022362:Hepatitis A Vaccines / Q000008:administration & dosage* / Q000276:immunology*; D006801:Humans; D007273:Injections, Intramuscular; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D011044:Poland / Q000453:epidemiology; D015995:Prevalence; D013997:Time Factors; D014611:Vaccination
D035922:Hepatitis A Antibodies; D022362:Hepatitis A Vaccines
AIDS; HIV; hepatitis A virus; hepatitis C; prognostic factors; response; vaccination